Clinical trial · Interventional
Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis
Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II
NCT00987246CI-TRIAL-00018682completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LAS106521 | Drug | — | UNRESOLVED |
| LAS41005 | Drug | — | UNRESOLVED |
| Placebo Gel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- LAS41005
- interventionNames
- Drug: LAS41005
- type
- ACTIVE_COMPARATOR
- label
- LAS106521
- interventionNames
- Drug: LAS106521
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- interventionNames
- Drug: Placebo Gel
Primary outcomes (1)
- measure
- Histological status of AK target lesion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Main Inclusion Criteria: * Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991 * Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception Main Exclusion Criteria: * Have received effective treatment of AK in the three months preceding this clinical trial * Have known hypersensitivity to LAS41005 or LAS106521 * Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma) * Patient's taking phenytoin * Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)
References
Publications (0)
Data not yet available
No reference posted for this study.